Results 51 to 60 of about 29,341 (237)

Subthreshold Aortic Valve Calcium Scores in Severe Aortic Stenosis and Transthyretin Cardiac Amyloidosis

JACC: Case Reports, 2020
We have clinically observed that some patients with transthyretin cardiac amyloidosis and severe aortic stenosis may have lesser degrees of calcification than one might expect.
Muzna Hussain, MD, Mazen Hanna, MD, Leonardo Rodriguez, MD, Brian Griffin, MD, Chris Watson, MD PhD, Dermot Phelan, MD, Paul Schoenhagen, MD, Wael Jaber, MD, Paul Cremer, MD, Patrick Collier, MD, PhD   +9 more
doaj   +1 more source

Amyloid Transthyretin Cardiomyopathy in Elderly Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background The prevalence of calcific aortic stenosis and amyloid transthyretin cardiomyopathy (ATTR‐CM) increase with age, and they often coexist. The objective was to determine the prevalence of ATTR‐CM in patients with severe aortic stenosis and ...
Stephan Dobner, Thomas Pilgrim, Daniel Hagemeyer, Dik Heg, Jonas Lanz, Nicole Reusser, Christoph Gräni, Ali Afshar‐Oromieh, Axel Rominger, Bettina Langhammer, David Reineke, Stephan Windecker, Stefan Stortecky   +12 more
doaj   +1 more source

Real‐world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study

ESC Heart Failure, Volume 12, Issue 2, Page 1203-1216, April 2025.
The 366 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) were analyzed regarding their clinical characteristics in the first year after approval of tafamidis 61 mg for ATTR‐CM in Germany. Nearly two‐thirds of the patients were in an advanced disease stage and 64% met the key criteria of the “Transthyretin Amyloidosis ...
Richard J. Nies, Svenja Ney, Ingrid Kindermann, Yvonne Bewarder, Angela Zimmer, Fabian Knebel, Katrin Hahn, Sebastian Spethmann, Peter Luedike, Lars Michel, Tienush Rassaf, Maria Papathanasiou, Stefan Störk, Vladimir Cejka, Amin Polzin, Fabian Voss, Malte Kelm, Bernhard Unsöld, Christine Meindl, Michael Paulus, Ali Yilmaz, Bishwas Chamling, Caroline Morbach, Roman Pfister   +23 more
wiley   +1 more source

A phenomap of TTR amyloidosis to aid diagnostic screening

ESC Heart Failure, Volume 12, Issue 2, Page 1113-1118, April 2025.
Abstract Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.
Alexios S. Antonopoulos, Theodoros Tsampras, George Lazaros, Konstantinos Tsioufis, Charalambos Vlachopoulos   +4 more
wiley   +1 more source

Serum Transthyretin [PDF]

Circulation: Heart Failure, 2018
See Article by Hanson et al > The future depends on what you do today. > > ―Mahatma Gandhi A biomarker is defined by the National Institutes of Health Biomarkers Definitions Working Group as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses ...
openaire   +2 more sources

Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study

ESC Heart Failure, Volume 12, Issue 2, Page 1326-1335, April 2025.
Abstract Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction.
Robin Willixhofer, Mauro Contini, Michele Emdin, Damiano Magrì, Alice Bonomi, Elisabetta Salvioni, Fabrizio Celeste, Alberico Del Torto, Claudio Passino, Christophe D.J. Capelle, Chiara Arzilli, Emiliano Fiori, Nicolò Capra, Christina Kronberger, Nikita Ermolaev, Andreas Kammerlander, Beatrice Musumeci, Giuseppe Vergaro, Vincenzo Castiglione, René Rettl, Giacomo Tini, Andrea Baggiano, Iacopo Fabiani, Susanna Sciomer, Roza Badr Eslam, Piergiuseppe Agostoni   +25 more
wiley   +1 more source

Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy

ESC Heart Failure
Aims Recognition of transthyretin amyloid cardiomyopathy is increasing due to advances in cardiac imaging and diagnostic strategies, but questions remain regarding disease frequency and characteristics.
Pablo Garcia‐Pavia, Thibaud Damy, Nicolas Piriou, Roberto Barriales‐Villa, Francesco Cappelli, Catherine Bahus, Carmen Munteanu, Denis Keohane, Pablo Mallaina, Perry Elliott, the TTRACK investigators   +10 more
doaj   +1 more source

Serum Transthyretin Level as a Plausible Marker for Diagnosis of Child Acute Malnutrition

Biochemistry Research International, 2017
Malnutrition is a major underlying condition for mortality in children under five years of age in developing countries, particularly in Ethiopia. The most important forms of malnutrition in Ethiopia are protein and energy deficiencies.
Behailu Tsegaye, Amha Mekasha, Solomon Genet   +2 more
doaj   +1 more source

Transthyretin: a multifaceted protein

BioMolecular Concepts, 2014
AbstractTransthyretin is a highly conserved homotetrameric protein, mainly synthetized by the liver and the choroid plexus of brain. The carrier role of TTR is well-known; however, many other functions have emerged, namely in the nervous system. Behavior, cognition, neuropeptide amidation, neurogenesis, nerve regeneration, axonal growth and 14-3-3ζ ...
Vieira Marta, Saraiva Maria João
openaire   +3 more sources

Comparative Stability and Clearance of [Met30]Transthyretin and [Met119]Transthyretin [PDF]

European Journal of Biochemistry, 1997
[Met119]Transthyretin has been described as a non‐amyloidogenic transthyretin variant. In Portugal, it has also been found in compound heterozygotic individual carriers of [Met30]transthyretin, the most prevalent variant associated with familial amyloidotic polyneuropathy.
I, Longo Alves, M T, Hays, M J, Saraiva
openaire   +2 more sources